Skip to main content

Table 1 Patient demographics

From: Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus

Variable Training (n = 41) Test (n = 23) Combined (n = 64a)
Age at diagnosis, mean (range) years 13.9 (7.5–18.1) 13.7 (9.5–18.1) 13.8 (7.5–18.1)
Sampling date, postdiagnosis (range) days 15 (0–62) 5 (0–32) 12 (0–62)
Number (%) females 37 (90) 20 (87) 57 (89)
ANA-positive patients (%) 40 (98) 23 (100) 63 (98)
dsDNA antibody-positive patients (%) 35 (83) 19 (83) 53 (83)
Class III/IV lupus nephritis-biopsy provenb (%) 23 (56) 8 (35) 31 (48)
Mean (range) SLEDAI score 14 (4–30) 14 (4–29) 14 (4–30)
Treatment at sample:    
 PO steroids (%) 17 (41) 4 (20) 21 (33)
 IV steroids (%) 18 (44) 1 (5) 19 (30)
 HCQ (%) 18 (44) 8 (40) 26 (41)
 Other IS (%) 6 (15) 0 (0) 6 (9)
 None 10 (24) 12 (60) 22 (34)
Hispanic (%) 16 (39) 9 (39) 25 (39)
Asian/Pacific Islander (%) 12 (29) 8 (35) 20 (31)
Non-Hispanic Caucasian (%) 10 (24) 5 (22) 15 (23)
Black (%) 2 (5) 1 (4) 3 (5)
  1. ANA antinuclear antibody, SLEDAI systemic lupus erythematosus disease activity index, PO per os, IV intravenous, HCQ hydroxychloroquine, IS immunosuppressive therapy (cyclophosphamide, mycophenolate, or methotrexate), None no treatment or NSAID alone
  2. aFour new-onset patients who were suspected to have proliferative nephritis, but were not biopsy-confirmed, were not included in the training and test sets, or these demographics. Similarly, two patients with class V nephritis were not included in the training and test sets, or these demographics
  3. bOne patient who developed class IV nephritis 4 years after her initial visit, and a second patient who developed class V nephritis 5 years after her initial visit, were considered negative for this analysis